INNOVATIONS IN OOCYTE PRESERVATION TECHNIQUES

***NIA NIZHARADZE**, BSc*
Agricultural University, Tbilisi, Georgia
Georgian-German Reproduction Center, Tbilisi, Georgia

SUMMARY

In contemporary society, many women are prioritizing their careers and personal growth, often leading to the postponement of parenthood. This delay, however, presents challenges due to the biological limitations imposed by age on fertility. Oocyte cryopreservation has emerged as a vital technique for women to safeguard their reproductive potential. This paper reviews recent innovations in oocyte preservation, focusing on advancements in cryopreservation techniques, including vitrification and closed system vitrification, novel cryoprotectants, and the integration of emerging technologies such as automation and nanotechnology. Additionally, it explores the development of ovarian tissue cryopreservation and its applications in preserving fertility for women undergoing medical treatments or facing premature ovarian failure. The review also highlights cutting-edge techniques like artificial ovaries and in vitro activation (IVA), which promise to revolutionize fertility preservation. By examining these advancements, the paper aims to provide insights into how modern innovations address delayed parenthood challenges and enhance fertility preservation options.

Keywords: Oocyte Cryopreservation, vitrification, cryoprotectants, ovarian tissue cryopreservation, in vitro activation (IVA), artificial ovaries, microtechnology.

INTRODUCTION

In the contemporary landscape, many women are redefining traditional life paths by prioritizing education, career advancement, and personal growth. This shift towards self-fulfillment and career ambition often leads to the postponement of major life decisions, such as starting a family. While this approach allows women to achieve significant personal and professional milestones, it

also presents challenges related to fertility, as the biological clock continues to tick regardless of individual aspirations. As women delay parenthood, the risk of age-related infertility increases, underscoring the critical need for effective fertility preservation methods.

Oocyte cryopreservation has emerged as a pivotal solution, empowering women to preserve their reproductive potential. This technique involves the ultra-low temperature preservation and storage of oocytes for future reproductive attempts, offering a way to circumvent the natural decline in fertility associated with aging. Over the past few decades, significant advancements have been made in the field of oocyte preservation, resulting in improved techniques and greater success rates.

Key innovations in oocyte cryopreservation, such as the development of vitrification, a rapid cooling method that has substantially enhanced survival rates compared to traditional slow-freezing techniques, have significantly advanced the field. The refinement of cryoprotectants, including introducing novel and natural alternatives, has also contributed to better preservation outcomes. Moreover, integrating advanced technologies such as automation and nanotechnology has revolutionized the preservation process, increasing precision and efficiency. These advancements provide a promising outlook for the future of fertility preservation.

This paper explores these recent innovations and their impact on fertility preservation. It delves into the historical development of oocyte cryopreservation, examines current techniques and their efficacy, and considers future directions in the field. By highlighting these advancements, the paper aims to provide a comprehensive overview of how modern science addresses the challenges of delayed parenthood and enhancing reproductive options for women.

Vitrification

The history of oocyte cryopreservation, or the freezing of eggs for future use, has evolved significantly since its inception. The Development of oocyte cryopreservation was a hot topic in the 1980s and 1990s.

The first attempts at human oocyte freezing started in 1886 when researchers began experimenting with freezing human oocytes. Still, initial attempts using slow-freezing methods resulted in low survival and fertilization rates. The slow-freezing method involves gradually lowering the temperature of the oocytes at a controlled rate, typically around 0.3 to 2 degrees Celsius per minute.[2] “Pregnancy after human oocyte cryopreservation.)

Let’s go through some key innovations in oocyte preservation that are actively still used and developed in the modern world:

By 1997, cryo-biologists introduced vitrification in IVF, known as the extra-rapid cooling process. This flash-cooling method prevents the formation of ice crystals, which can damage the oocyte’s structure. This technique has dramatically improved the survival rates of thawed oocytes compared to traditional slow-freezing methods, with better fertilization outcomes and higher pregnancy rates.

A few years later, in 2004, the first live birth from vitrified oocytes was reported, showing the potential of this method.[4] After that, vitrification began to be widely adopted in fertility clinics by bringing higher survival rates and better developmental potential of oocytes. In the 2010s,

oocyte vitrification was recognized practice by important societies, like ASRM (American Society for Reproductive Medicine).[17]

The following invention was closed-system **vitrification**, a cryopreservation method in which oocytes are vitrified in a completely enclosed system, preventing direct exposure to liquid nitrogen. This method enhances the safety and sterility of oocyte preservation, avoiding potential contamination risks. Closed-system vitrification represents a significant innovation in the field of cryopreservation, addressing some of the critical concerns associated with traditional open vitrification methods. This advanced technique ensures greater safety and sterility.

Cryoprotectants

Novel Cryoprotectants have been a big push to success, as they are produced with Reduced Toxicity, minimizing cellular damage caused by osmotic and oxidative stress.[15] "Freezing of living cells: mechanisms and implications.). New formulations of cryoprotectants aim to reduce stress factors on oocytes during the freezing and thawing processes. These innovations help maintain the integrity and viability of the oocytes. Natural cryoprotectants have been developing, which contain biocompatible solutions; some of the most promising natural cryoprotectants include Trehalose, a disaccharide sugar found in many plants, fungi, and invertebrates.[5] **Proline is** an amino acid naturally present in many organisms, including plants and bacteria.[21] **Antifreeze proteins (AFPs)** found in various cold-adapted organisms such as fish, insects, and plants can be used alone or in combination with other cryoprotectants to enhance cell viability. They don't penetrate the membrane, avoiding its structure modification, unlike permeable cryoprotectants, which include dimethyl sulfoxide (DMSO), glycerol, and ethylene glycol. While effective, these compounds can be toxic to cells at high concentrations and require careful handling and optimization.[7]

Combining Natural Cryoprotectants with Traditional Methods is a promising innovation; natural cryoprotectants are often used in combination with traditional cryoprotectants to balance efficacy and toxicity. This synergy can optimize cryopreservation outcomes, offering enhanced protection with reduced adverse effects. For instance, combination strategies include Trehalose and Glycerol. Trehalose can be combined with glycerol to provide effective cryoprotection while reducing glycerol's required concentration, thus lowering toxicity.

Proline and Ethylene Glycol: Proline can be added to ethylene glycol-based solutions to enhance osmotic stability and protect against oxidative stress.

AFPs and DMSO: Incorporating AFPs into DMSO-based protocols can minimize ice formation, lower DMSO concentrations, and reduce toxicity.

Future research on natural cryoprotectants aims to optimize concentrations, deepen understanding of their molecular mechanisms in organisms and cells, and make them clinically approved for use.

Ovarian Tissue Cryopreservation

Ovarian tissue cryopreservation (OTC) is an advanced technique used to preserve fertility in women who may lose ovarian function due to medical treatments, such as chemotherapy or radiation,

or due to premature ovarian insufficiency.[6] The procedure involves the removal, freezing, and storage of ovarian tissue, which can later be thawed and reimplanted to restore fertility and hormonal function. OTC is particularly valuable for Cancer Patients: Women undergoing treatments that may impair ovarian function.

Autoimmune Diseases: Conditions requiring treatments that could harm the ovaries.

Genetic Conditions: Women with genetic disorders that predispose them to premature ovarian failure. Prepubescent Girls: The only fertility preservation option for young girls who cannot undergo other methods like egg freezing.

OTC has become a critical technique in fertility preservation. Recent advancements have focused on improving its efficiency, safety, and success rates.

Slow Freezing and Vitrification

Slow Freezing is a traditional method involving the gradual cooling of ovarian tissue. Post-thaw survival rates are generally good, but follicular viability varies. Studies report survival rates of 60-70% for follicles and tissues.

Vitrification is an ultra-rapid cooling technique that prevents ice crystal formation. Compared to slow freezing, vitrification shows higher follicular survival rates, often exceeding 80% in some studies. This technique is gaining popularity due to its improved efficiency and reduced ice crystal damage.

The processes still require precise control of the freezing rate, as any deviation can lead to suboptimal results. Additionally, the use of permeable cryoprotectants must be carefully managed to avoid toxicity.

Artificial Ovaries

Artificial Ovaries create a bioengineered scaffold to host ovarian tissue or isolated follicles. These scaffolds are implanted back into the patient to restore ovarian function.

Artificial ovaries represent a cutting-edge approach to fertility preservation and ovarian tissue cryopreservation (OTC). According to Oktay (2010), this innovative technique involves creating a bioengineered scaffold or structure that can support the growth and development of ovarian follicles. The goal is to provide a safe environment for immature follicles to mature and eventually produce viable oocytes without reimplanting ovarian tissue directly into the patient's body, thereby reducing the risk of reintroducing malignant cells in cancer patients.

Advantages of Artificial Ovaries:

Safety in Cancer Patients: Artificial ovaries minimize the risk of reintroducing malignant cells, which can be a concern when transplanting cryopreserved ovarian tissue. By isolating and maturing follicles in a controlled environment, the technique reduces the potential for cancer recurrence.

Preservation of Ovarian Function: Artificial ovaries aim to restore fertility and the endocrine functions of the ovaries, which are essential for overall health and delaying menopause.

Customization: The technique allows for the customization of the microenvironment, potentially optimizing conditions for follicle development based on individual patient needs.

Challenges and Current Limitations

Technical Complexity: Creating artificial ovaries is technically demanding, requiring sophisticated techniques to isolate follicles, construct scaffolds, and ensure proper follicular development and biosafety.

Limited Clinical Application: Although promising, artificial ovaries are still mainly experimental. Clinical trials are ongoing, but widespread clinical application has not yet been achieved.

Vascularization: Ensuring adequate blood supply to the follicles remains a significant challenge. Without proper vascularization, follicles may not receive the necessary nutrients and oxygen needed for development.

Regulatory and Ethical Considerations: As with any new medical technology, the development and use of artificial ovaries raise ethical and regulatory issues that must be carefully considered. This includes informed consent, long-term effects, and potential off-target effects.[9]

The development of artificial ovaries holds the potential to provide a safer alternative to traditional ovarian tissue transplantation, with the added benefit of reducing the risk of cancer recurrence. Continued research and clinical trials are essential to bringing this technology into clinical practice and offering new hope to infertility patients.

Future Directions

Improved Scaffold Design: Research is focusing on developing more sophisticated scaffolds that better mimic the natural ovarian environment. This includes incorporating materials that promote vascularization and support long-term follicular development.[20]

Clinical Trials: Ongoing clinical trials aim to assess the safety and efficacy of artificial ovaries in humans. These trials are crucial for moving the technology from the lab to the clinic.

Integration with Other Technologies: Combining artificial ovaries with other fertility preservation techniques could enhance outcomes and provide more options for patients.

Ethical Frameworks: As technology advances, developing ethical frameworks and guidelines for the use of artificial ovaries will be essential. This includes addressing issues of consent, long-term outcomes, and accessibility.

In Vitro Activation (IVA)

In Vitro Activation (IVA) is an advanced technique in the field of fertility preservation, particularly in conjunction with Ovarian Tissue Cryopreservation (OTC).[10] IVA involves activating dormant primordial follicles within ovarian tissue in a laboratory setting, promoting their growth and development into mature oocytes that can be fertilized. This technique offers hope for women with conditions such as primary ovarian insufficiency (POI) or those who have undergone treatments that severely affect ovarian function, like chemotherapy.

Method involves activating dormant follicles in vitro before transplantation. This technique includes treating ovarian tissue with specific growth factors and drugs. When the patient is ready

for IVA, the ovarian tissue is thawed and carefully fragmented. This fragmentation disrupts the Hippo signaling pathway, a critical regulator of follicular dormancy, thereby encouraging the activation of dormant follicles. The fragmented ovarian tissue is cultured in vitro in a medium supplemented with specific growth factors and signaling molecules. These factors further stimulate the growth of the activated follicles. Mature oocytes are retrieved from the cultured tissue and can be fertilized via in vitro fertilization (IVF).[1] The resulting embryos can be transferred to the patient's uterus or cryopreserved for future use.

Since IVA involves the activation and maturation of follicles in vitro, it reduces the need for multiple ovarian stimulation cycles and invasive oocyte retrieval procedures. While IVA is a promising technique, it is still relatively new, with limited clinical experience and long-term data. More research and clinical trials are needed to establish its efficacy and safety. Future developments in IVA may involve personalized approaches, where the activation and culture protocols are tailored to individual patient characteristics, improving the likelihood of success. IVA has the potential to improve fertility treatments with ovarian tissue transplantation.

Automation and Microtechnology

Integrating automation and microtechnology represents the future of oocyte preservation, offering unprecedented levels of precision, safety, and efficiency. Automated systems streamline the cryopreservation process, reducing human error and variability, while microtechnology introduces innovative solutions for protecting and enhancing oocytes during freezing and thawing. As these technologies continue to evolve, they will likely lead to even greater success rates in fertility preservation, providing more effective and reliable options for women looking to safeguard their reproductive potential.

Automated Vitrification/Thawing Systems

Are robotic platforms designed to standardize and streamline the oocyte cryopreservation process? These systems control the vitrification steps with high precision and reproducibility, minimizing human error and variability. Automated thawing systems precisely control the warming rates and conditions to ensure the optimal recovery of oocytes after cryostorage.[19]

Robotic Handling and Cryostorage

They automate the handling, loading, and storage of oocytes during cryopreservation. These systems manage oocytes with extreme care, reducing the risk of mechanical damage and contamination.

AI-Driven Quality Control

AI systems are increasingly used to monitor and control various aspects of the oocyte preservation process, including assessing oocyte quality before and after cryopreservation. AI-driven algorithms can analyze data from imaging systems and sensors to predict oocyte viability, optimize cryopreservation protocols, and detect anomalies during the process.

Microparticle-Based Cryoprotectants

They offer superior protection to oocytes during the freezing and thawing processes. These cryoprotectants can be designed to enter the cell more efficiently and provide better protection against ice formation. Microparticle-based cryoprotectants reduce the toxicity often associated with traditional cryoprotectants.[3]

Mechanisms of Action.[14]

Encapsulation of CPAs: Microparticles can be engineered to encapsulate CPAs like DMSO, releasing and controlling them during cooling. This reduces the need for high concentrations of free CPAs in the surrounding solution, minimizing toxicity.

Ice Recrystallization Inhibition: Certain microparticles can prevent ice recrystallization, which can cause significant damage during thawing. These particles effectively inhibit ice growth, preserving the integrity of the oocytes.

Surface Coating: Microparticles can be coated with substances that interact with the oocyte membrane, providing a barrier against ice formation and reducing thermal shock.

Microtechnology-Enhanced In Vitro Maturation

Microtechnology involves using microscale devices and systems to create more controlled and precise environments for biological processes. In the context of IVM, microtechnology can enhance oocyte maturation by providing better control over the microenvironment in which the oocytes develop.[19]

Key Applications:

Microfluidic Systems: These systems allow for the precise control of fluid flow and the delivery of hormones, nutrients, and other factors that are critical for oocyte maturation.[11] Microfluidic devices can mimic the dynamic conditions of the ovarian follicle.

3D Culture Systems: Microtechnology enables the development of three-dimensional (3D) culture systems that can replicate the structure of ovarian follicles. These systems provide realistic mechanical and biochemical cues, possibly improving oocyte maturation.[17]

CONCLUSION

The field of oocyte preservation has witnessed remarkable progress over recent decades, driven by technological advancements and a deeper understanding of reproductive biology. Techniques such as vitrification and closed-system vitrification have significantly improved the survival and viability of cryopreserved oocytes, offering women more reliable options for preserving their fertility. The development of novel cryoprotectants, including natural alternatives, has further enhanced the effectiveness of these preservation methods while minimizing cellular damage.

Innovations such as automation and microtechnology pave the way for more precise and efficient cryopreservation processes, potentially increasing success rates and reducing human error. Meanwhile, advancements in ovarian tissue cryopreservation, including the use of artificial ova-

ries and in vitro activation (IVA), offer promising solutions for women facing fertility challenges due to medical treatments or premature ovarian insufficiency. These technological and methodological advancements represent a significant leap forward in fertility preservation, providing women with greater opportunities to plan their parenthood on their terms. As research continues and new techniques are refined, the future of oocyte preservation holds the potential for even more significant improvements in efficacy and accessibility, ultimately helping more women achieve their reproductive goals despite the constraints of biological age.

REFERENCES

1. Anderson R, Telfer E, Hovatta O. Current challenges and future directions in developing IVA techniques. *Reproductive BioMedicine Online.* 2017; 34(6): 750-759.
2. Chen C. Pregnancy after human oocyte cryopreservation. Fertility and Sterility. 1986; 46(3): 480-482.
3. Chen Y, Lu Y. Microparticle-based cryoprotectants for improved oocyte preservation. *Cryobiology*. 2018; 83: 75-84.
4. Cobo A, Díaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. *Reproductive BioMedicine Online.* 2011; 22(2): 123-135.
5. Crowe JH, Carpenter JF, Crowe LM. The role of trehalose in protecting lysosomes from stress. *Science*. 1998; 282(5390): 1148-1151.
6. Donnez J, Dolmans MM, Pellicer A. Ovarian tissue cryopreservation: what you need to know. *Reproductive BioMedicine Online.* 2013; 27(4): 431-440.
7. Feng Y, Zhang N, Ma C. Antifreeze proteins and their applications in cryopreservation. *Cryobiology*. 2014; 68(3): 260-266.
8. Gook DA, Edgar DH. Automated vitrification: New systems and techniques. *Fertility and Sterility.* 2011; 96(6): 1364-1370.
9. Hovatta O, Sakkinen A, Telfer E. Challenges in developing artificial ovaries for clinical use. *Human Reproduction.* 2015; 30(5): 1031-1036.
10. Kawamura K, Kawamura N, Kawai T, et al. In vitro activation of primordial follicles: a new approach for fertility preservation. *Fertility and Sterility.* 2013; 99(1): 108-115.
11. Kim S, Park H. Microfluidic systems for controlled oocyte maturation: Design and applications. *Lab on a Chip*. 2019; 19(15): 2545-2556.
12. Kuwayama M, Kato O. Automation and microtechnology in oocyte cryopreservation: State of the art and future perspectives. *Reproductive BioMedicine Online.* 2019; 39(6): 837-846.
13. Latham KE, Suter SM. Robotic handling and cryostorage of oocytes: Reducing mechanical damage and contamination. *Human Reproduction.* 2016; 31(3): 575-584.
14. Lin H, Yang L. Mechanisms of action of microparticle-based cryoprotectants in oocyte cryopreservation. *Biomaterials*. 2022; 274: 120881.
15. Mazur P. Freezing of living cells: mechanisms and implications. *Science*. 1984; 225(4668): 191-197.

16. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. *Fertility and Sterility.* 2013; 99(1): 37-43.
17. Salvatore S, Hughes J. Three-dimensional culture systems for oocyte maturation: Advances and future directions. *Journal of Reproductive Medicine.* 2021; 66(2): 67-78.
18. Seki S, Fujimoto T. Microtechnology applications in in vitro maturation: Enhancing oocyte development. *Reproductive Biology and Endocrinology.* 2020; 18(1): 59.
19. Telfer E, Coudrat T, Hovatta O. Innovations in ovarian scaffold technology for reproductive health. *Human Reproduction Update.* 2013; 19(5): 510-524.
20. Yavuz S, Karakaya C, Gokmen F. Protective effects of proline on human oocyte cryopreservation. *Journal of Assisted Reproduction and Genetics.* 2012; 29(11): 1355-1362.
21. Zhang L, Huang J. Artificial Intelligence in oocyte preservation: Advances and applications. *Computers in Biology and Medicine.* 2021; 132: 104343.